Epidemiologic classification of human papillomavirus types associated with cervical cancer
- PMID: 12571259
- DOI: 10.1056/NEJMoa021641
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Abstract
Background: Infection with human papilloma virus (HPV) is the main cause of cervical cancer, but the risk associated with the various HPV types has not been adequately assessed.
Methods: We pooled data from 11 case-control studies from nine countries involving 1918 women with histologically confirmed squamous-cell cervical cancer and 1928 control women. A common protocol and questionnaire were used. Information on risk factors was obtained by personal interviews, and cervical cells were collected for detection of HPV DNA and typing in a central laboratory by polymerase-chain-reaction-based assays (with MY09/MY11 and GP5+/6+ primers).
Results: HPV DNA was detected in 1739 of the 1918 patients with cervical cancer (90.7 percent) and in 259 of the 1928 control women (13.4 percent). With the GP5+/6+ primer, HPV DNA was detected in 96.6 percent of the patients and 15.6 percent of the controls. The most common HPV types in patients, in descending order of frequency, were types 16, 18, 45, 31, 33, 52, 58, and 35. Among control women, types 16, 18, 45, 31, 6, 58, 35, and 33 were the most common. For studies using the GP5+/6+ primer, the pooled odds ratio for cervical cancer associated with the presence of any HPV was 158.2 (95 percent confidence interval, 113.4 to 220.6). The odds ratios were over 45 for the most common and least common HPV types. Fifteen HPV types were classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82); 3 were classified as probable high-risk types (26, 53, and 66); and 12 were classified as low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108). There was good agreement between our epidemiologic classification and the classification based on phylogenetic grouping.
Conclusions: In addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 should be considered carcinogenic, or high-risk, types, and types 26, 53, and 66 should be considered probably carcinogenic.
Copyright 2003 Massachusetts Medical Society
Comment in
-
Adding a test for human papillomavirus DNA to cervical-cancer screening.N Engl J Med. 2003 Feb 6;348(6):489-90. doi: 10.1056/NEJMp020178. N Engl J Med. 2003. PMID: 12571255 No abstract available.
-
Classification of human papillomavirus.N Engl J Med. 2003 May 15;348(20):2040-1; author reply 2040-1. doi: 10.1056/NEJM200305153482022. N Engl J Med. 2003. PMID: 12748326 No abstract available.
-
Type-specific testing for human papillomavirus.N Engl J Med. 2003 Aug 7;349(6):614-5. doi: 10.1056/NEJM200308073490619. N Engl J Med. 2003. PMID: 12904531 No abstract available.
Similar articles
-
[Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].Mikrobiyol Bul. 2008 Apr;42(2):273-82. Mikrobiyol Bul. 2008. PMID: 18697425 Turkish.
-
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.J Natl Cancer Inst. 2006 Mar 1;98(5):303-15. doi: 10.1093/jnci/djj067. J Natl Cancer Inst. 2006. PMID: 16507827
-
HPV types and cofactors causing cervical cancer in Peru.Br J Cancer. 2001 Sep 28;85(7):966-71. doi: 10.1054/bjoc.2001.1948. Br J Cancer. 2001. PMID: 11592767 Free PMC article.
-
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer.N Engl J Med. 1999 Nov 25;341(22):1633-8. doi: 10.1056/NEJM199911253412201. N Engl J Med. 1999. PMID: 10572150
-
Human papillomavirus and cancer: the epidemiological evidence.J Clin Virol. 2000 Oct;19(1-2):1-5. doi: 10.1016/s1386-6532(00)00125-6. J Clin Virol. 2000. PMID: 11091143 Review.
Cited by
-
Type-specific persistence or regression of human papillomavirus genotypes in women with cervical intraepithelial neoplasia 1: A prospective cohort study.Obstet Gynecol Sci. 2015 Jan;58(1):40-5. doi: 10.5468/ogs.2015.58.1.40. Epub 2015 Jan 16. Obstet Gynecol Sci. 2015. PMID: 25629017 Free PMC article.
-
HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study.Vaccines (Basel). 2021 Apr 1;9(4):336. doi: 10.3390/vaccines9040336. Vaccines (Basel). 2021. PMID: 33916132 Free PMC article.
-
Oxidative stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues.PLoS One. 2012;7(3):e34366. doi: 10.1371/journal.pone.0034366. Epub 2012 Mar 28. PLoS One. 2012. PMID: 22470562 Free PMC article.
-
Effectiveness of glycyrrhizinic Acid (glizigen) and an immunostimulant (viusid) to treat anogenital warts.ISRN Dermatol. 2012;2012:863692. doi: 10.5402/2012/863692. Epub 2012 Aug 14. ISRN Dermatol. 2012. PMID: 22957266 Free PMC article.
-
Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria.Int J Cancer. 2012 Dec 15;131(12):2903-9. doi: 10.1002/ijc.27563. Epub 2012 Apr 27. Int J Cancer. 2012. PMID: 22473652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous